Key Points
- SVP Michael Pisetsky sold 20,756 shares on Feb. 17 at an average price of $15.35 for $318,604.60, reducing his stake by 6.77% to 285,974 shares (about $4.39M).
- Institutional buying has accelerated, led by First Light Asset Management which added 3,115,001 shares to reach 5,032,904 shares (~$99.25M); overall institutional ownership stands at 98.11%.
- Wall Street is broadly bullish with a consensus rating of "Moderate Buy" and an average price target of $24.33, after multiple upgrades and raised targets from firms including Morgan Stanley, Canaccord and Needham.
SiBone (NASDAQ:SIBN - Get Free Report) SVP Michael Pisetsky sold 20,756 shares of the business's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $15.35, for a total transaction of $318,604.60. Following the transaction, the senior vice president directly owned 285,974 shares in the company, valued at approximately $4,389,700.90. The trade was a 6.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.
SiBone Trading Up 3.2%
NASDAQ:SIBN opened at $15.74 on Thursday. The company has a 50-day moving average price of $17.97 and a 200-day moving average price of $16.86. The stock has a market cap of $682.96 million, a price-to-earnings ratio of -30.86 and a beta of 0.69. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21. SiBone has a 12 month low of $12.49 and a 12 month high of $21.89.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the business. First Light Asset Management LLC boosted its position in shares of SiBone by 162.4% during the fourth quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company's stock valued at $99,249,000 after buying an additional 3,115,001 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of SiBone by 22.5% during the 3rd quarter. American Century Companies Inc. now owns 2,838,107 shares of the company's stock valued at $41,777,000 after acquiring an additional 521,683 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of SiBone by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 2,501,555 shares of the company's stock worth $49,331,000 after acquiring an additional 11,566 shares during the period. Nuveen LLC raised its holdings in shares of SiBone by 5.1% during the fourth quarter. Nuveen LLC now owns 1,421,946 shares of the company's stock valued at $28,041,000 after purchasing an additional 69,229 shares during the last quarter. Finally, Impax Asset Management Group plc lifted its position in SiBone by 17.1% during the fourth quarter. Impax Asset Management Group plc now owns 1,200,010 shares of the company's stock valued at $23,664,000 after purchasing an additional 175,000 shares during the period. 98.11% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on SIBN shares. TD Cowen upgraded SiBone to a "strong-buy" rating in a research report on Tuesday, January 27th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SiBone in a research report on Monday, December 29th. Morgan Stanley lifted their price target on shares of SiBone from $20.00 to $23.00 and gave the company an "overweight" rating in a research report on Tuesday, December 2nd. Canaccord Genuity Group upped their price objective on shares of SiBone from $26.00 to $27.00 and gave the stock a "buy" rating in a report on Wednesday, December 17th. Finally, Needham & Company LLC lifted their target price on shares of SiBone from $24.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $24.33.
Get Our Latest Stock Analysis on SIBN
About SiBone
(
Get Free Report)
Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
